HP 288 Cytokine Restraining Agent: Began a Phase I/II trial in cancer patients with advanced malignancy

Houghten Pharmaceuticals Inc. Product: HP 288 Cytokine Restraining Agent, a small molecule compound to restrain the pathological effects of cytokines without interfering with their immune functions Us...